This update serves to correct an error in fact. Third-quarter revenue derived from Genome Therapeutics' GenomeVision division fell by $1.3 million year over year, not $4.2 million as originally reported. GenomeWeb regrets the error.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.